Lv11
86 积分 2024-06-21 加入
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
5小时前
待确认
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
11天前
已完结
Bioengineering strategies to optimize STING agonist therapy
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
3个月前
已完结
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
5个月前
已完结
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
6个月前
已完结
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
7个月前
已完结
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
8个月前
已完结
The prostate cancer drug market
8个月前
已完结
皖公网安备34019202002308
